Page 1 EFFECT OF VITAMIN K ON BONE MINERAL DENSITY AND FRACTURES IN ADULTS: AN UPDATED SYSTEMATIC REVIEW AND META-ANALYSIS OF RANDOMISED CONTROLLED TRIALS Andrew Mott 1* , Thomas Bradley 2 , Kath Wright 3 , Elizabeth Sarah Cockayne 1 , Martin J Shearer 4 , Joy Adamson 5 , Susan Alexandra Lanham- New 6 , David J Torgerson 1 1. York Trials Unit, Department of Health Sciences, University of York, York, YO10 5DD 2. Chesterfield Hospital, Chesterfield Road, Calow, United Kingdom, S44 5BL 3. Centre for Reviews & Dissemination, University of York, York, YO10 5DD 4. Centre for Haemostasis and Thrombosis, Guy’s and St Thomas’ NHS Trust, London SE1 7EH 5. Institute of Health & Society, Newcastle University, Baddiley-Clark Building, Richardson Road, Newcastle upon Tyne, NE2 4AX 6. Nutritional Sciences Department, School of Biosciences and Medicine, Faculty of Health and Medical Sciences, University of Surrey, Guildford, GU2 7XH *Correspondence to: Andrew Mott E: [email protected]T: 0044 (0)1904 321 727 1 2 3 4 5 6 7 8 9 10 11 12 13 14 15 16 17 18 19 20 21 22
43
Embed
eprints.whiterose.ac.ukeprints.whiterose.ac.uk/145682/1/Main_text_final.docx · Web viewFor post-menopausal or osteoporotic patients meta-analysis showed that the odds of any clinical
This document is posted to help you gain knowledge. Please leave a comment to let me know what you think about it! Share it to your friends and learn new things together.
Transcript
Page 1
EFFECT OF VITAMIN K ON BONE MINERAL DENSITY AND FRACTURES IN ADULTS:
AN UPDATED SYSTEMATIC REVIEW AND META-ANALYSIS OF RANDOMISED
CONTROLLED TRIALS
Andrew Mott1*, Thomas Bradley2, Kath Wright3, Elizabeth Sarah Cockayne1, Martin J
Shearer4, Joy Adamson5, Susan Alexandra Lanham-New6, David J Torgerson1
1. York Trials Unit, Department of Health Sciences, University of York, York, YO10 5DD
2. Chesterfield Hospital, Chesterfield Road, Calow, United Kingdom, S44 5BL
3. Centre for Reviews & Dissemination, University of York, York, YO10 5DD
4. Centre for Haemostasis and Thrombosis, Guy’s and St Thomas’ NHS Trust, London SE1
7EH
5. Institute of Health & Society, Newcastle University, Baddiley-Clark Building,
Richardson Road, Newcastle upon Tyne, NE2 4AX
6. Nutritional Sciences Department, School of Biosciences and Medicine, Faculty of Health
and Medical Sciences, University of Surrey, Guildford, GU2 7XH
1. Cockayne S, Adamson J, Lanham-New S, Shearer MJ, Gilbody S, Torgerson DJ (2006) Vitamin K and the prevention of fractures: systematic review and meta-analysis of randomized controlled trials. Arch Intern Med 166 (12):1256-1261. doi:10.1001/archinte.166.12.12562. Torgerson DJ (2018) Caution to Readers About Systematic Review on Vitamin K and Prevention of Fractures That Included Problematic Trials. JAMA Intern Med 178 (6):863-864. doi:10.1001/jamainternmed.2018.11273. Bolland MJ, Avenell A, Gamble GD, Grey A (2016) Systematic review and statistical analysis of the integrity of 33 randomized controlled trials. Neurology 87 (23):2391-2402. doi:10.1212/WNL.00000000000033874. Sato Y, Honda Y, Iwamoto J (2018) RETRACTED: Etidronate for fracture prevention in amyotrophic lateral sclerosis: A randomized controlled trial. Bone 106:214. doi:10.1016/j.bone.2017.10.0085. Booth SL (2009) Roles for vitamin K beyond coagulation. Annu Rev Nutr 29:89-110. doi:10.1146/annurev-nutr-080508-1412176. Bügel S (2008) Vitamin K and Bone Health in Adult Humans. 78:393-416. doi:10.1016/s0083-6729(07)00016-77. Gundberg CM, Lian JB, Booth SL (2012) Vitamin K-dependent carboxylation of osteocalcin: friend or foe? Adv Nutr 3 (2):149-157. doi:10.3945/an.112.0018348. Liu G, Peacock M (1998) Age-Related Changes in Serum Undercarboxylated Osteocalcin and its Relationships with Bone Density, Bone Quality, and Hip Fracture. Calcified Tissue International 62 (4):286-289. doi:10.1007/s0022399004329. Szulc P, Chapuy MC, Meunier PJ, Delmas PD (1993) Serum undercarboxylated osteocalcin is a marker of the risk of hip fracture in elderly women. J Clin Invest 91 (4):1769-1774. doi:10.1172/JCI11638710. Szulc P, Arlot M, Chapuy MC, Duboeuf F, Meunier PJ, Delmas PD (1994) Serum undercarboxylated osteocalcin correlates with hip bone mineral density in elderly women. J Bone Miner Res 9 (10):1591-1595. doi:10.1002/jbmr.565009101211. Vergnaud P, Garnero P, Meunier PJ, Breart G, Kamihagi K, Delmas PD (1997) Undercarboxylated osteocalcin measured with a specific immunoassay predicts hip fracture in elderly women: the EPIDOS Study. J Clin Endocrinol Metab 82 (3):719-724. doi:10.1210/jcem.82.3.380512. Booth SL, Broe KE, Peterson JW, Cheng DM, Dawson-Hughes B, Gundberg CM, Cupples LA, Wilson PW, Kiel DP (2004) Associations between vitamin K biochemical measures and bone mineral density in men and women. J Clin Endocrinol Metab 89 (10):4904-4909. doi:10.1210/jc.2003-03167313. Marshall D, Johnell O, Wedel H (1996) Meta-analysis of how well measures of bone mineral density predict occurrence of osteoporotic fractures. Bmj 312 (7041):1254-1259. doi:10.1136/bmj.312.7041.125414. Hao G, Zhang B, Gu M, Chen C, Zhang Q, Zhang G, Cao X (2017) Vitamin K intake and the risk of fractures: A meta-analysis. Medicine (Baltimore) 96 (17):e6725. doi:10.1097/MD.000000000000672515. Garner P, Hopewell S, Chandler J, MacLehose H, Schunemann HJ, Akl EA, Beyene J, Chang S, Churchill R, Dearness K, Guyatt G, Lefebvre C, Liles B, Marshall R, Martinez Garcia L, Mavergames C, Nasser M, Qaseem A, Sampson M, Soares-Weiser K, Takwoingi Y, Thabane L, Trivella M, Tugwell P, Welsh E, Wilson EC, Schunemann HJ, Panel for updating guidance for systematic r (2016) When and how to update systematic reviews: consensus and checklist. BMJ 354:i3507. doi:10.1136/bmj.i350716. RETRACTION: Risedronate therapy for prevention of hip fracture after stroke in elderly women; Risedronate therapy for prevention of hip fracture after stroke in elderly women. Reply from the Authors (2016). Neurology 87 (2):239. doi:10.1212/WNL.000000000000278817. Kupferschmidt K (2018) Researcher at the center of an epic fraud remains an enigma to those who exposed him. Science. doi:10.1126/science.aav1079
18. Poisot T (2011) The digitize Package: Extracting Numerical Data from Scatterplots. The R Journal 3 (1):25-2619. Higgins JP, Altman DG, Gotzsche PC, Juni P, Moher D, Oxman AD, Savovic J, Schulz KF, Weeks L, Sterne JA, Cochrane Bias Methods G, Cochrane Statistical Methods G (2011) The Cochrane Collaboration's tool for assessing risk of bias in randomised trials. BMJ 343:d5928. doi:10.1136/bmj.d592820. Hicks A, Fairhurst C, Torgerson DJ (2018) A simple technique investigating baseline heterogeneity helped to eliminate potential bias in meta-analyses. J Clin Epidemiol 95:55-62. doi:10.1016/j.jclinepi.2017.10.00121. Higgins JPT, Green S (2011) Cochrane Handbook for Systematic Reviews of Interventions, vol 5.1.0. doi:10.1002/978047071218422. Sterne JA, Sutton AJ, Ioannidis JP, Terrin N, Jones DR, Lau J, Carpenter J, Rucker G, Harbord RM, Schmid CH, Tetzlaff J, Deeks JJ, Peters J, Macaskill P, Schwarzer G, Duval S, Altman DG, Moher D, Higgins JP (2011) Recommendations for examining and interpreting funnel plot asymmetry in meta-analyses of randomised controlled trials. BMJ 343:d4002. doi:10.1136/bmj.d400223. Viechtbauer W (2010) Conducting Meta-Analyses inRwith themetaforPackage. Journal of Statistical Software 36 (3). doi:10.18637/jss.v036.i0324. R Development Core Team (2017) R: A Language and Environment for Statistical Computing. 3.4.0 edn. R Foundation for Statistical Computing, Vienna, Austria25. Booth SL, Dallal G, Shea MK, Gundberg C, Peterson JW, Dawson-Hughes B (2008) Effect of vitamin K supplementation on bone loss in elderly men and women. J Clin Endocrinol Metab 93 (4):1217-1223. doi:10.1210/jc.2007-249026. Bolton-Smith C, McMurdo ME, Paterson CR, Mole PA, Harvey JM, Fenton ST, Prynne CJ, Mishra GD, Shearer MJ (2007) Two-year randomized controlled trial of vitamin K1 (phylloquinone) and vitamin D3 plus calcium on the bone health of older women. J Bone Miner Res 22 (4):509-519. doi:10.1359/jbmr.07011627. Binkley N, Harke J, Krueger D, Engelke J, Vallarta-Ast N, Gemar D, Checovich M, Chappell R, Suttie J (2009) Vitamin K treatment reduces undercarboxylated osteocalcin but does not alter bone turnover, density, or geometry in healthy postmenopausal North American women. J Bone Miner Res 24 (6):983-991. doi:10.1359/jbmr.08125428. Braam LA, Knapen MH, Geusens P, Brouns F, Vermeer C (2003) Factors affecting bone loss in female endurance athletes: a two-year follow-up study. Am J Sports Med 31 (6):889-895. doi:10.1177/0363546503031006260129. Braam LAJLM, Knapen MHJ, Geusens P, Brouns F, Hamulyk K, Gerichhausen MJW, Vermeer C (2003) Vitamin K1 Supplementation Retards Bone Loss in Postmenopausal Women Between 50 and 60 Years of Age. Calcified Tissue International 73 (1):21-26. doi:10.1007/s00223-002-2084-430. Cheung AM, Tile L, Lee Y, Tomlinson G, Hawker G, Scher J, Hu H, Vieth R, Thompson L, Jamal S, Josse R (2008) Vitamin K supplementation in postmenopausal women with osteopenia (ECKO trial): a randomized controlled trial. PLoS Med 5 (10):e196. doi:10.1371/journal.pmed.005019631. Emaus N, Gjesdal CG, Almas B, Christensen M, Grimsgaard AS, Berntsen GK, Salomonsen L, Fonnebo V (2010) Vitamin K2 supplementation does not influence bone loss in early menopausal women: a randomised double-blind placebo-controlled trial. Osteoporos Int 21 (10):1731-1740. doi:10.1007/s00198-009-1126-432. Forli L, Bollerslev J, Simonsen S, Isaksen GA, Kvamsdal KE, Godang K, Gadeholt G, Pripp AH, Bjortuft O (2010) Dietary vitamin K2 supplement improves bone status after lung and heart transplantation. Transplantation 89 (4):458-464. doi:10.1097/TP.0b013e3181c46b6933. Fulton RL, McMurdo ME, Hill A, Abboud RJ, Arnold GP, Struthers AD, Khan F, Vermeer C, Knapen MH, Drummen NE, Witham MD (2016) Effect of Vitamin K on Vascular Health and Physical Function in Older People with Vascular Disease--A Randomised Controlled Trial. J Nutr Health Aging 20 (3):325-333. doi:10.1007/s12603-015-0619-4
34. Gleeson D, Hodges S, Rigney E, Blumsohn A, Hannon R, Peel N, Eastell R (2003) 740 Placebo-controlled trial of vitamin K supplementation on bone mineral density in primary biliary cirrhosis(PBC). Hepatology 38:516-516. doi:10.1016/s0270-9139(03)80782-635. Hirao M, Hashimoto J, Ando W, Ono T, Yoshikawa H (2008) Response of serum carboxylated and undercarboxylated osteocalcin to alendronate monotherapy and combined therapy with vitamin K2 in postmenopausal women. J Bone Miner Metab 26 (3):260-264. doi:10.1007/s00774-007-0823-336. Hozuki T, Imai T, Tsuda E, Matsumura A, Yamamoto D, Toyoshima T, Suzuki S, Yamauchi R, Hayashi T, Hisahara S, Shimohama S (2010) Response of Serum Carboxylated and Undercarboxylated Osteocalcin to Risedronate Monotherapy and Combined Therapy with Vitamin K2 in Corticosteroid-Treated Patients: A Pilot Study. Internal Medicine 49 (5):371-376. doi:10.2169/internalmedicine.49.255137. Inoue K, Hamano T, Nango N, Matsui I, Tomida K, Mikami S, Fujii N, Nakano C, Obi Y, Shimomura A, Kusunoki Y, Rakugi H, Isaka Y, Tsubakihara Y (2014) Multidetector-row computed tomography is useful to evaluate the therapeutic effects of bisphosphonates in glucocorticoid-induced osteoporosis. J Bone Miner Metab 32 (3):271-280. doi:10.1007/s00774-013-0485-238. Inoue T, Fujita T, Kishimoto H, Makino T, Nakamura T, Nakamura T, Sato T, Yamazaki K (2009) Randomized controlled study on the prevention of osteoporotic fractures (OF study): a phase IV clinical study of 15-mg menatetrenone capsules. J Bone Miner Metab 27 (1):66-75. doi:10.1007/s00774-008-0008-839. Ishida Y, Kawai S (2004) Comparative efficacy of hormone replacement therapy, etidronate, calcitonin, alfacalcidol, and vitamin K in postmenopausal women with osteoporosis: The Yamaguchi Osteoporosis Prevention Study. Am J Med 117 (8):549-555. doi:10.1016/j.amjmed.2004.05.01940. Iwamoto I, Kosha S, Noguchi S-i, Murakami M, Fujino T, Douchi T, Nagata Y (1999) A longitudinal study of the effect of vitamin K2 on bone mineral density in postmenopausal women a comparative study with vitamin D3 and estrogen–progestin therapy. Maturitas 31 (2):161-164. doi:10.1016/s0378-5122(98)00114-541. Je SH, Joo NS, Choi BH, Kim KM, Kim BT, Park SB, Cho DY, Kim KN, Lee DJ (2011) Vitamin K supplement along with vitamin D and calcium reduced serum concentration of undercarboxylated osteocalcin while increasing bone mineral density in Korean postmenopausal women over sixty-years-old. J Korean Med Sci 26 (8):1093-1098. doi:10.3346/jkms.2011.26.8.109342. Jiang Y, Zhang ZL, Zhang ZL, Zhu HM, Wu YY, Cheng Q, Wu FL, Xing XP, Liu JL, Yu W, Meng XW (2014) Menatetrenone versus alfacalcidol in the treatment of Chinese postmenopausal women with osteoporosis: a multicenter, randomized, double-blinded, double-dummy, positive drug-controlled clinical trial. Clin Interv Aging 9:121-127. doi:10.2147/CIA.S5410743. Jokar M, Mirfeizi Z, Esmaili H, M K (2016) Effect of Vitamin K and Alendronate Combination Treatment on Bone Mineral Density of Postmenopausal Osteoporosis Patients: A Pilot Study. Patient Safety & Quality Improvement 4 (1):320-333. doi:dx.doi.org/10.22038/psj.2016.628844. Retraction blues (2013). Nat Med 19 (12):1547-1548. doi:10.1038/nm.342645. Kanellakis S, Moschonis G, Tenta R, Schaafsma A, van den Heuvel EG, Papaioannou N, Lyritis G, Manios Y (2012) Changes in parameters of bone metabolism in postmenopausal women following a 12-month intervention period using dairy products enriched with calcium, vitamin D, and phylloquinone (vitamin K(1)) or menaquinone-7 (vitamin K (2)): the Postmenopausal Health Study II. Calcif Tissue Int 90 (4):251-262. doi:10.1007/s00223-012-9571-z46. Kasukawa Y, Miyakoshi N, Ebina T, Aizawa T, Hongo M, Nozaka K, Ishikawa Y, Saito H, Chida S, Shimada Y (2014) Effects of risedronate alone or combined with vitamin K2 on serum undercarboxylated osteocalcin and osteocalcin levels in postmenopausal osteoporosis. J Bone Miner Metab 32 (3):290-297. doi:10.1007/s00774-013-0490-547. Knapen MH, Drummen NE, Smit E, Vermeer C, Theuwissen E (2013) Three-year low-dose menaquinone-7 supplementation helps decrease bone loss in healthy postmenopausal women. Osteoporos Int 24 (9):2499-2507. doi:10.1007/s00198-013-2325-6
48. Knapen MH, Schurgers LJ, Vermeer C (2007) Vitamin K2 supplementation improves hip bone geometry and bone strength indices in postmenopausal women. Osteoporos Int 18 (7):963-972. doi:10.1007/s00198-007-0337-949. Koitaya N, Sekiguchi M, Tousen Y, Nishide Y, Morita A, Yamauchi J, Gando Y, Miyachi M, Aoki M, Komatsu M, Watanabe F, Morishita K, Ishimi Y (2014) Low-dose vitamin K2 (MK-4) supplementation for 12 months improves bone metabolism and prevents forearm bone loss in postmenopausal Japanese women. J Bone Miner Metab 32 (2):142-150. doi:10.1007/s00774-013-0472-750. Moschonis G, Kanellakis S, Papaioannou N, Schaafsma A, Manios Y (2011) Possible site-specific effect of an intervention combining nutrition and lifestyle counselling with consumption of fortified dairy products on bone mass: the Postmenopausal Health Study II. J Bone Miner Metab 29 (4):501-506. doi:10.1007/s00774-010-0256-251. Nishiguchi S, Shimoi S, Kurooka H, Tamori A, Habu D, Takeda T, Ochi H (2001) Randomized pilot trial of vitamin K2 for bone loss in patients with primary biliary cirrhosis. Journal of Hepatology 35 (4):543-545. doi:10.1016/s0168-8278(01)00133-752. O'Connor EM, Grealy G, McCarthy J, Desmond A, Craig O, Shanahan F, Cashman KD (2014) Effect of phylloquinone (vitamin K1) supplementation for 12 months on the indices of vitamin K status and bone health in adult patients with Crohn's disease. Br J Nutr 112 (7):1163-1174. doi:10.1017/S000711451400191353. Ronn SH, Harslof T, Pedersen SB, Langdahl BL (2016) Vitamin K2 (menaquinone-7) prevents age-related deterioration of trabecular bone microarchitecture at the tibia in postmenopausal women. Eur J Endocrinol 175 (6):541-549. doi:10.1530/EJE-16-049854. Purwosunu Y, Muharram, Rachman IA, Reksoprodjo S, Sekizawa A (2006) Vitamin K2 treatment for postmenopausal osteoporosis in Indonesia. J Obstet Gynaecol Res 32 (2):230-234. doi:10.1111/j.1447-0756.2006.00386.x55. Sasaki N, Kusano E, Takahashi H, Ando Y, Yano K, Tsuda E, Asano Y (2005) Vitamin K2 inhibits glucocorticoid-induced bone loss partly by preventing the reduction of osteoprotegerin (OPG). J Bone Miner Metab 23 (1):41-47. doi:10.1007/s00774-004-0539-656. Shiomi S, Nishiguchi S, Kubo S, Tamori A, Habu D, Takeda T, Ochi H (2002) Vitamin K2 (menatetrenone) for bone loss in patients with cirrhosis of the liver. Am J Gastroenterol 97 (4):978-981. doi:10.1111/j.1572-0241.2002.05618.x57. Shiraki M, Itabashi A (2009) Short-term menatetrenone therapy increases gamma-carboxylation of osteocalcin with a moderate increase of bone turnover in postmenopausal osteoporosis: a randomized prospective study. J Bone Miner Metab 27 (3):333-340. doi:10.1007/s00774-008-0034-658. Shiraki M, Shiraki Y, Aoki C, Miura M (2000) Vitamin K2 (menatetrenone) effectively prevents fractures and sustains lumbar bone mineral density in osteoporosis. J Bone Miner Res 15 (3):515-521. doi:10.1359/jbmr.2000.15.3.51559. Somekawa Y, Chigughi M, Harada M, Ishibashi T (1999) Use of vitamin K2 (menatetrenone) and 1,25-dihydroxyvitamin D3 in the prevention of bone loss induced by leuprolide. J Clin Endocrinol Metab 84 (8):2700-2704. doi:10.1210/jcem.84.8.592060. Tanaka S, Miyazaki T, Uemura Y, Miyakawa N, Gorai I, Nakamura T, Fukunaga M, Ohashi Y, Ohta H, Mori S, Hagino H, Hosoi T, Sugimoto T, Itoi E, Orimo H, Shiraki M (2017) Comparison of concurrent treatment with vitamin K2 and risedronate compared with treatment with risedronate alone in patients with osteoporosis: Japanese Osteoporosis Intervention Trial-03. J Bone Miner Metab 35 (4):385-395. doi:10.1007/s00774-016-0768-561. Ushiroyama T, Ikeda A, Ueki M (2002) Effect of continuous combined therapy with vitamin K2 and vitamin D3 on bone mineral density and coagulofibrinolysis function in postmenopausal women. Maturitas 41 (3):211-221. doi:10.1016/s0378-5122(01)00275-462. Volpe SL, Leung MM, Giordano H (2008) Vitamin K supplementation does not significantly impact bone mineral density and biochemical markers of bone in pre- and perimenopausal women. Nutr Res 28 (9):577-582. doi:10.1016/j.nutres.2008.06.006
63. Yuko M, Hitoshi S, Masao K, Hiromitsu F, Satoshi M, Takashi K, Yasuhiko K, Tatsuya A, Teruo H, Katsuhiko A, Yasuhiko T (2014) Poster Session - PS3 - 036 RISEDRONATE COMBINED WITH MENATETRENONE MAY PREVENT GLUCOCORTICOID-INDUCED OSTEOPOROSIS IN PATIENTS WITH CHRONIC
GLOMERULONEPHRITIS. Nephrology 19:77-202. doi:10.1111/nep.1223764. Holden RM, Booth SL, Day AG, Clase CM, Zimmerman D, Moist L, Shea MK, McCabe KM, Jamal SA, Tobe S, Weinstein J, Madhumathi R, Adams MA, Heyland DK (2015) Inhibiting the progression of arterial calcification with vitamin K in HemoDialysis patients (iPACK-HD) trial: rationale and study design for a randomized trial of vitamin K in patients with end stage kidney disease. Can J Kidney Health Dis 2:17. doi:10.1186/s40697-015-0053-x65. Hampson G (2015) Vitamin K as Additive Treatment in Osteoporosis. https://ClinicalTrials.gov/show/NCT01232647. 66. Genant HK, Li J, Wu CY, JA S (2000) Vertebral Fractures in Osteoporosis: A New Method for Clinical Assessment. J Clin Densitom 3:281-29067. Fukunaga M, Nakamura T, Shiraki M, Kuroda T, Ohta H, Hosoi T, Orimo H (2004) Absolute height reduction and percent height ratio of the vertebral body in incident fracture in Japanese women. J Bone Miner Metab 22 (2):104-110. doi:10.1007/s00774-003-0457-z68. Tai V, Leung W, Grey A, Reid IR, Bolland MJ (2015) Calcium intake and bone mineral density: systematic review and meta-analysis. BMJ 351:h4183. doi:10.1136/bmj.h418369. Veronese N, Bano G, Bertozzo G, Granziera S, Solmi M, Manzato E, Sergi G, Cohen AT, Correll CU (2015) Vitamin K antagonists' use and fracture risk: results from a systematic review and meta-analysis. J Thromb Haemost 13 (9):1665-1675. doi:10.1111/jth.1305270. Bach AU, Anderson SA, Foley AL, Williams EC, Suttie JW (1996) Assessment of vitamin K status in human subjects administered "minidose" warfarin. Am J Clin Nutr 64 (6):894-902. doi:10.1093/ajcn/64.6.89471. Huang ZB, Wan SL, Lu YJ, Ning L, Liu C, Fan SW (2015) Does vitamin K2 play a role in the prevention and treatment of osteoporosis for postmenopausal women: a meta-analysis of randomized controlled trials. Osteoporos Int 26 (3):1175-1186. doi:10.1007/s00198-014-2989-672. Su S, He N, Men P, Song C, Zhai S (2019) The efficacy and safety of menatetrenone in the management of osteoporosis: a systematic review and meta-analysis of randomized controlled trials. Osteoporos Int. doi:10.1007/s00198-019-04853-773. Newman P, Shearer MJ (2008) Metabolism and cell biology of vitamin K. Thrombosis and Haemostasis 100 (10):530-547. doi:10.1160/th08-03-014774. Ballane G, Cauley JA, Luckey MM, El-Hajj Fuleihan G (2017) Worldwide prevalence and incidence of osteoporotic vertebral fractures. Osteoporos Int 28 (5):1531-1542. doi:10.1007/s00198-017-3909-375. Shea MK, Booth SL (2016) Concepts and Controversies in Evaluating Vitamin K Status in Population-Based Studies. Nutrients 8 (1). doi:10.3390/nu8010008
Figure 1: A PRISMA flow diagram of study selection
Figure 2: Meta-analysis of Peto odds ratio of any clinical fracture outcomes for trials including Osteoporotic or Postmenopausal participants
Figure 3: Meta-analysis of Peto odds ratio of any vertebral fracture outcomes for trials including Osteoporotic or Postmenopausal participants
Figure 4: Meta-analyses of mean difference in percentage change from baseline in Bone Mineral Density at 12 months for trials including Osteoporotic or Postmenopausal participants
Figure 5: Meta-analyses of mean difference in percentage change from baseline in Bone Mineral Density at 24 months for trials including Osteoporotic or Postmenopausal participants